Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

China-Biotics, Inc. NASDAQ:CHBT

|Includes: China-Biotics, Inc. (CHBT)

China-Biotics, Inc. NASDAQ:CHBT 2011 Price target $20 Analysis by Chutinush Taksinapinunt ,Corporate Account Executive, Heffernan Capital Management

China-Biotics, Inc. NASDAQ:CHBT (”China-Biotics” or “the Company”), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements in China.

Through its wholly owned subsidiaries, Shanghai Shining Biotechnology Co., Ltd. and Growing Bioengineering (Shanghai) Co. Ltd., the Company develops and produces a proprietary product portfolio.

Currently, its retail products are sold over the counter, mainly through large distributors, to pharmacies and supermarkets in Shanghai and Jiangsu and Zhejiang provinces.

The Company China-Biotics, Inc. NASDAQ:CHBT also sells bulk products to institutional customers such as dairy and animal feed producers as well as pharmaceutical companies. In February 2010, China-Biotics began its commercial production in China’s largest probiotics production facility to meet growing demand in China.

China-Biotics, Inc. NASDAQ:CHBT is one of just a few Chinese food companies that have received four major international certifications — including HACCP, a U.S. FDA designation required for all food imports into the U.S. And CHBT’s probiotics have a survival rate of 70% at room temperature two years after manufacture — twice the requirement for probiotic products sold in Europe, it says.

Because of its superior fermentation technology, the company’s products also have a much higher active ingredient concentration than most domestic competitors.

In fact, many of its domestic competitors use outdated technology to manufacture probiotics, which tend to be inferior and have a shorter shelf life.

China-Biotics, Inc. NASDAQ:CHBT

Full Report